Exploring Patient Treatment Experience with Subcutaneous C1INH Prophylaxis for Hereditary Angioedema:
Impact on Breakthrough Attacks, Quality of Life, and Rescue Medication Use
Retrospective Analysis of Patient Outcomes Associated with Subcutaneous C1INH Prophylaxis for Hereditary Angioedema
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorLonghurst H, Cicardi M, Craig T, et al.
N Engl J Med 2017
Long-term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksCraig T, Zuraw B, Longhurst H, et al.
J Allergy Clin Immunol Pract 2019
Important Safety Information for HAEGARDA
HAEGARDA®, C1 Esterase Inhibitor Subcutaneous (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older. HAEGARDA is for subcutaneous use after reconstitution only.
HAEGARDA is contraindicated in patients with a history of life-threatening hypersensitivity reactions, including anaphylaxis, to C1-INH preparations or their excipients.
Severe hypersensitivity reactions to HAEGARDA could occur. In such cases, discontinue administration and institute appropriate treatment. Epinephrine should be immediately available to treat hypersensitivity reactions.
At the recommended subcutaneous dose of HAEGARDA, no causal relationship to thromboembolic events (TEs) has been established. However, TEs have been reported with intravenous administration of C1-INH products, usually at high doses.
In clinical trials, adverse reactions observed in more than 4% of subjects treated with HAEGARDA were injection-site reactions, hypersensitivity, nasopharyngitis, and dizziness.
HAEGARDA is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.
Please see full prescribing information for HAEGARDA.